论文部分内容阅读
目的:探究甲基强的松龙联合中剂量环磷酰胺(CTX)治疗重症肌无力危象(MGC)的临床效果及安全性。方法:选取2012年1月~2015年6月在我院神经内科就诊的MGC患者90例,随机分为对照组(45例)和观察组(45例),对照组患者接受甲基强的松龙治疗,观察组采用甲基强的松龙联合中剂量CTX治疗。比较两组患者的临床疗效及不良反应的发生情况。结果:观察组患者呼吸困难消失时间、吞咽功能恢复时间和肢体无力症状改善时间均明显短于对照组(P<0.05);观察组用药7 d内治疗有效率86.7%明显高于对照组(P<0.05),肺部感染发生率20%,较对照组显著降低,差异均具有统计学意义(P<0.05)。结论:甲基强的松龙联合中剂量CTX可有效提高MGC的治疗效果,促进患者早日康复,且肺部感染的发生率降低。
Objective: To investigate the clinical efficacy and safety of methylprednisolone combined with medium dose cyclophosphamide (CTX) in the treatment of myasthenia gravis crisis (MGC). Methods: 90 patients with MGC treated in Department of Neurology from January 2012 to June 2015 were randomly divided into control group (45 cases) and observation group (45 cases). Patients in the control group received methylprednisone Long treatment, the observation group using methylprednisolone combined with CTX treatment. The clinical efficacy and adverse reactions of the two groups were compared. Results: The disappearance time of dyspnea, the recovery time of swallowing function and the improvement of limb weakness in observation group were significantly shorter than those in control group (P <0.05). The treatment effective rate in observation group within 7 days was significantly higher than that in control group (86.7%, P <0.05). The incidence of pulmonary infection was 20%, which was significantly lower than that of the control group (P <0.05). Conclusion: Combination of methylprednisolone and mid-dose of CTX can effectively improve the therapeutic effect of MGC, promote the early recovery of patients, and reduce the incidence of pulmonary infection.